Optimal P2Y 12 Inhibitor for Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: Network Meta-Analysis in the Data-Free Zone: Do You Believe in Magic?

JACC: Cardiovascular Interventions

Volumn 9, Issue 10, 2016, Pages 1047-1050

  Cuisset, Thomas ^a   Capodanno, Davide ^b   Wijns, William ^c,d  

^a INSERM   (France)

^b UNIVERSITY OF CATANIA   (Italy)

^c OLV HOSPITAL   (Belgium)

^d NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

antiplatelet treatment; glycoprotein IIb IIIa antagonists; primary PCI; STEMI

Indexed keywords

CANGRELOR; CLOPIDOGREL; HIRULOG; PRASUGREL; TICAGRELOR; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR;

BLEEDING; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; HUMAN; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NOTE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; HEART INFARCTION; NETWORK META-ANALYSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON, CORONARY; HUMANS; MYOCARDIAL INFARCTION; NETWORK META-ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; ST ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

EID: 84968719158     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2016.03.040     Document Type: Editorial

References (12)

1. 12 inhibitor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a network meta-analysis J Am Coll Cardiol Intv 9 2016 1036 1046
2. S. Windecker, P. Kolh, F. Alfonso, and et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Eur Heart J 35 2014 2541 2619
3. G.N. Levine, E.R. Bates, J.A. Bittl, and et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines J Am Coll Cardiol 2016 Mar 23 [E-pub ahead of print]
4. P. Vranckx, D.E. Cutlip, R. Mehran, and et al. Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies EuroIntervention 5 2010 871 874
5. 12 inhibition in ST-segment elevation myocardial infarction: bridging the gap Am Heart J 170 2015 3 12
6. D. Alexopoulos, K.C. Theodoropoulos, E.F. Stavrou, and et al. Prasugrel versus high dose clopidogrel to overcome early high on clopidogrel platelet reactivity in patients with ST elevation myocardial infarction Cardiovasc Drugs Ther 26 2012 393 400
7. G. Parodi, R. Valenti, B. Bellandi, and et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study J Am Coll Cardiol 61 2013 1601 1606
8. G. Parodi, I. Xanthopoulou, B. Bellandi, and et al. Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study J Am Coll Cardiol 65 2015 511 512
9. Rollini F, Franchi F, Hu J, Kureti M, et al. Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention: the CRUSH study. J Am Coll Cardiol.67:1994-2004.
10. D. Capodanno, and D.J. Angiolillo Pretreatment with antiplatelet drugs in invasively managed patients with coronary artery disease in the contemporary era: review of the evidence and practice guidelines Circ Cardiovasc Interv 8 2015 e002301
11. G. Christ, T. Hafner, J.M. Siller-Matula, and et al. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy Thromb Res 132 2013 e36 e41
12. M. Valgimigli, M. Tebaldi, G. Campo, and et al. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation Through Aggrastat by Dropping or Shortening Infusion Line in Patients With ST-Segment Elevation Myocardial Infarction Compared to or on Top of Prasugrel Given at Loading Dose) trial J Am Coll Cardiol Intv 5 2012 268 277